Differential expression of microRNAs in Alzheimer's disease brain, blood, and cerebrospinal fluid. 2019

Petros Takousis, and Angélique Sadlon, and Jessica Schulz, and Inken Wohlers, and Valerija Dobricic, and Lefkos Middleton, and Christina M Lill, and Robert Perneczky, and Lars Bertram
Ageing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, London, UK.

Several microRNAs (miRNAs) have been implicated in Alzheimer's disease pathogenesis, but the evidence from individual case-control studies remains inconclusive. A systematic literature review was performed, followed by standardized multistage data extraction, quality control, and meta-analyses on eligible data for brain, blood, and cerebrospinal fluid specimens. Results were compared with miRNAs reported in the abstracts of eligible studies or recent qualitative reviews to assess novelty. Data from 147 independent data sets across 107 publications were quantitatively assessed in 461 meta-analyses. Twenty-five, five, and 32 miRNAs showed studywide significant differential expression (α < 1·08 × 10-4) in brain, cerebrospinal fluid, and blood-derived specimens, respectively, with 5 miRNAs showing differential expression in both brain and blood. Of these 57 miRNAs, 13 had not been reported in the abstracts of previous original or review articles. Our systematic assessment of differential miRNA expression is the first of its kind in Alzheimer's disease and highlights several miRNAs of potential relevance.

UI MeSH Term Description Entries
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D057890 Epigenomics The systematic study of the global gene expression changes due to EPIGENETIC PROCESSES and not due to DNA base sequence changes. Epigenetics,Epigenetic,Epigenomic
D035683 MicroRNAs Small double-stranded, non-protein coding RNAs, 21-25 nucleotides in length generated from single-stranded microRNA gene transcripts by the same RIBONUCLEASE III, Dicer, that produces small interfering RNAs (RNA, SMALL INTERFERING). They become part of the RNA-INDUCED SILENCING COMPLEX and repress the translation (TRANSLATION, GENETIC) of target RNA by binding to homologous 3'UTR region as an imperfect match. The small temporal RNAs (stRNAs), let-7 and lin-4, from C. elegans, are the first 2 miRNAs discovered, and are from a class of miRNAs involved in developmental timing. RNA, Small Temporal,Small Temporal RNA,miRNA,stRNA,Micro RNA,MicroRNA,Primary MicroRNA,Primary miRNA,miRNAs,pre-miRNA,pri-miRNA,MicroRNA, Primary,RNA, Micro,Temporal RNA, Small,miRNA, Primary,pre miRNA,pri miRNA

Related Publications

Petros Takousis, and Angélique Sadlon, and Jessica Schulz, and Inken Wohlers, and Valerija Dobricic, and Lefkos Middleton, and Christina M Lill, and Robert Perneczky, and Lars Bertram
January 2014, Neurobiology of aging,
Petros Takousis, and Angélique Sadlon, and Jessica Schulz, and Inken Wohlers, and Valerija Dobricic, and Lefkos Middleton, and Christina M Lill, and Robert Perneczky, and Lars Bertram
January 1987, Gerontology,
Petros Takousis, and Angélique Sadlon, and Jessica Schulz, and Inken Wohlers, and Valerija Dobricic, and Lefkos Middleton, and Christina M Lill, and Robert Perneczky, and Lars Bertram
January 2023, Frontiers in aging neuroscience,
Petros Takousis, and Angélique Sadlon, and Jessica Schulz, and Inken Wohlers, and Valerija Dobricic, and Lefkos Middleton, and Christina M Lill, and Robert Perneczky, and Lars Bertram
January 2017, Journal of Alzheimer's disease : JAD,
Petros Takousis, and Angélique Sadlon, and Jessica Schulz, and Inken Wohlers, and Valerija Dobricic, and Lefkos Middleton, and Christina M Lill, and Robert Perneczky, and Lars Bertram
November 2021, BMC medicine,
Petros Takousis, and Angélique Sadlon, and Jessica Schulz, and Inken Wohlers, and Valerija Dobricic, and Lefkos Middleton, and Christina M Lill, and Robert Perneczky, and Lars Bertram
December 2011, World journal of psychiatry,
Petros Takousis, and Angélique Sadlon, and Jessica Schulz, and Inken Wohlers, and Valerija Dobricic, and Lefkos Middleton, and Christina M Lill, and Robert Perneczky, and Lars Bertram
July 2017, Brain and nerve = Shinkei kenkyu no shinpo,
Petros Takousis, and Angélique Sadlon, and Jessica Schulz, and Inken Wohlers, and Valerija Dobricic, and Lefkos Middleton, and Christina M Lill, and Robert Perneczky, and Lars Bertram
January 2014, Journal of Alzheimer's disease : JAD,
Petros Takousis, and Angélique Sadlon, and Jessica Schulz, and Inken Wohlers, and Valerija Dobricic, and Lefkos Middleton, and Christina M Lill, and Robert Perneczky, and Lars Bertram
January 2011, Journal of Alzheimer's disease : JAD,
Petros Takousis, and Angélique Sadlon, and Jessica Schulz, and Inken Wohlers, and Valerija Dobricic, and Lefkos Middleton, and Christina M Lill, and Robert Perneczky, and Lars Bertram
January 2018, Journal of Alzheimer's disease : JAD,
Copied contents to your clipboard!